These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25449036)

  • 1. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
    Kataoka H; Yang K; Rock KL
    Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the treatment options for gout and calcium pyrophosphate deposition.
    Choy G
    Expert Opin Pharmacother; 2005 Nov; 6(14):2443-53. PubMed ID: 16259576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-κB.
    Raeispour M; Talebpour Amiri F; Farzipour S; Ghasemi A; Hosseinimehr SJ
    Drug Chem Toxicol; 2022 Nov; 45(6):2586-2593. PubMed ID: 34538151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
    Hosoya T; Ohno I
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M; Reid G
    J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat versus allopurinol for gout.
    Lustberg ME
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
    [No Abstract]   [Full Text] [Related]  

  • 17. Febuxostat for the treatment of gout.
    Bridgeman MB; Chavez B
    Expert Opin Pharmacother; 2015 Feb; 16(3):395-8. PubMed ID: 25556668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
    Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
    J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis.
    Gasse P; Riteau N; Charron S; Girre S; Fick L; Pétrilli V; Tschopp J; Lagente V; Quesniaux VF; Ryffel B; Couillin I
    Am J Respir Crit Care Med; 2009 May; 179(10):903-13. PubMed ID: 19218193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.